139 related articles for article (PubMed ID: 21156337)
1. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.
Ploussard G; Durand X; Xylinas E; Moutereau S; Radulescu C; Forgue A; Nicolaiew N; Terry S; Allory Y; Loric S; Salomon L; Vacherot F; de la Taille A
Eur Urol; 2011 Mar; 59(3):422-9. PubMed ID: 21156337
[TBL] [Abstract][Full Text] [Related]
2. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
[TBL] [Abstract][Full Text] [Related]
3. The role of biopsy core number in selecting prostate cancer patients for active surveillance.
Ploussard G; Xylinas E; Salomon L; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
Eur Urol; 2009 Dec; 56(6):891-8. PubMed ID: 19683860
[TBL] [Abstract][Full Text] [Related]
4. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
5. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
6. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
Hessels D; van Gils MP; van Hooij O; Jannink SA; Witjes JA; Verhaegh GW; Schalken JA
Prostate; 2010 Jan; 70(1):10-6. PubMed ID: 19708043
[TBL] [Abstract][Full Text] [Related]
8. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
10. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
11. [Does PCA3 score and prostatic MRI help selection of patients scheduled for initial prostatic biopsy?].
Vinet M; Vlaeminck-Guillem V; Rouvière O; Perrin P; Paparel P; Devonec M; Adam E; Briant PE; Ruffion A
Prog Urol; 2013 Feb; 23(2):121-7. PubMed ID: 23352305
[TBL] [Abstract][Full Text] [Related]
12. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
13. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.
Auprich M; Chun FK; Ward JF; Pummer K; Babaian R; Augustin H; Luger F; Gutschi S; Budäus L; Fisch M; Huland H; Graefen M; Haese A
Eur Urol; 2011 Jan; 59(1):96-105. PubMed ID: 20980098
[TBL] [Abstract][Full Text] [Related]
14. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
Whitson JM; Porten SP; Hilton JF; Cowan JE; Perez N; Cooperberg MR; Greene KL; Meng MV; Simko JP; Shinohara K; Carroll PR
J Urol; 2011 May; 185(5):1656-60. PubMed ID: 21419438
[TBL] [Abstract][Full Text] [Related]
15. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
16. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.
Auprich M; Haese A; Walz J; Pummer K; de la Taille A; Graefen M; de Reijke T; Fisch M; Kil P; Gontero P; Irani J; Chun FK
Eur Urol; 2010 Nov; 58(5):727-32. PubMed ID: 20619529
[TBL] [Abstract][Full Text] [Related]
17. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy.
Lerner SE; Blute ML; Zincke H
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):12-20; discussion 21. PubMed ID: 8725887
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.
Perdonà S; Cavadas V; Di Lorenzo G; Damiano R; Chiappetta G; Del Prete P; Franco R; Azzarito G; Scala S; Arra C; De Sio M; Autorino R
Eur Urol; 2011 Jan; 59(1):81-7. PubMed ID: 20947244
[TBL] [Abstract][Full Text] [Related]
20. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
